The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups

(2018) Tjalling Bosse et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival

(2017) Casey M. Cosgrove et al.   GYNECOLOGIC ONCOLOGY

Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma

(2017) Mariano Russo et al.   HUMAN PATHOLOGY

Identifying Lynch Syndrome in Women Presenting With Endometrial Carcinoma Under the Age of 50 Years

(2017) Antonios Anagnostopoulos et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium

(2017) Martin Köbel et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology

(2017) Antonia R. Sepulveda et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

(2017) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing

(2017) Jonathan A. Nowak et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

The genetic landscape of endometrial clear cell carcinomas

(2017) Deborah F DeLair et al.   JOURNAL OF PATHOLOGY

CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence

(2017) Katherine C Kurnit et al.   MODERN PATHOLOGY

Novel Implications in Molecular Diagnosis of Lynch Syndrome

(2017) Raffaella Liccardo et al.   Gastroenterology Research and Practice

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition

(2017) Florine A. Eggink et al.   OncoImmunology

Unusual Mismatch Repair Immunohistochemical Patterns in Endometrial Carcinoma

(2016) Jaclyn C. Watkins et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

L1CAM expression in endometrial carcinomas: an ENITEC collaboration study

(2016) Louis JM van der Putten et al.   BRITISH JOURNAL OF CANCER

Regression of Chemotherapy-Resistant Polymerase   (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab

(2016) A. D. Santin et al.   CLINICAL CANCER RESEARCH

Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis

(2016) M. K. McConechy et al.   CLINICAL CANCER RESEARCH

Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts

(2016) Ellen Stelloo et al.   CLINICAL CANCER RESEARCH

Accuracy of preoperative endometrial sampling diagnosis for predicting the final pathology grading in uterine endometrioid carcinoma

(2016) T.P. Batista et al.   EJSO

Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study

(2016) Martin Köbel et al.   GYNECOLOGIC ONCOLOGY

Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment

(2016) Aline Talhouk et al.   GYNECOLOGIC ONCOLOGY

TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers

(2016) Anne M. Schultheis et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

(2016) Janice M. Mehnert et al.   JOURNAL OF CLINICAL INVESTIGATION

Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels

(2016) Zsofia K. Stadler et al.   JOURNAL OF CLINICAL ONCOLOGY

Erratum: Molecular genetic heterogeneity in undifferentiated endometrial carcinomas

(2016) Juan M Rosa-Rosa et al.   MODERN PATHOLOGY

Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer

(2016) Inge C Van Gool et al.   MODERN PATHOLOGY

Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers

(2016) Inge C. van Gool et al.   JAMA Oncology

Just how accurate are the major risk stratification systems for early-stage endometrial cancer?

(2015) S Bendifallah et al.   BRITISH JOURNAL OF CANCER

A clinically applicable molecular-based classification for endometrial cancers

(2015) A Talhouk et al.   BRITISH JOURNAL OF CANCER

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

(2015) I. C. van Gool et al.   CLINICAL CANCER RESEARCH

Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas

(2015) M.K. McConechy et al.   GYNECOLOGIC ONCOLOGY

Histopathological features of endometrial carcinomas associated withPOLEmutations: implications for decisions about adjuvant therapy

(2015) Salwa Bakhsh et al.   HISTOPATHOLOGY

Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer: a validation study of the Gynecologic Oncology Group criteria

(2015) Tae Wook Kong et al.   Journal of Gynecologic Oncology

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

(2015) Ellen Stelloo et al.   MODERN PATHOLOGY

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

(2015) Brooke E. Howitt et al.   JAMA Oncology

L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results

(2014) T. Bosse et al.   EUROPEAN JOURNAL OF CANCER

Mismatch repair pathway

(2014) Aga Syed Sameer et al.   EUROPEAN JOURNAL OF CANCER PREVENTION

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

(2014) S. D. Brown et al.   GENOME RESEARCH

Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication

(2014) Eve Shinbrot et al.   GENOME RESEARCH

1A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group trial

(2014) D.S. McMeekin et al.   GYNECOLOGIC ONCOLOGY

Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer

(2014) Mariam M. AlHilli et al.   GYNECOLOGIC ONCOLOGY

DNA polymerase ε and its roles in genome stability

(2014) Erin E. Henninger et al.   IUBMB LIFE

Clinical Significance of CTNNB1 Mutation and Wnt Pathway Activation in Endometrioid Endometrial Carcinoma

(2014) Yuexin Liu et al.   JNCI-Journal of the National Cancer Institute

Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations

(2014) Yaser R Hussein et al.   MODERN PATHOLOGY

Practice Bulletin No. 147

(2014)   OBSTETRICS AND GYNECOLOGY

Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes

(2014) Siân Jones et al.   Nature Communications

Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma

(2013) C. Blake Gilks et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) N. Colombo et al.   ANNALS OF ONCOLOGY

Lack of Estrogen Receptor-  Is Associated with Epithelial-Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma

(2013) E. Wik et al.   CLINICAL CANCER RESEARCH

Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial

(2013) Jone Trovik et al.   EUROPEAN JOURNAL OF CANCER

DNA polymerase ɛ and δ exonuclease domain mutations in endometrial cancer

(2013) David N. Church et al.   HUMAN MOLECULAR GENETICS

L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation

(2013) Alain G. Zeimet et al.   JNCI-Journal of the National Cancer Institute

Reproducibility of histological cell type in high-grade endometrial carcinoma

(2013) Guangming Han et al.   MODERN PATHOLOGY

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤70years

(2012) Celine H.M. Leenen et al.   GYNECOLOGIC ONCOLOGY

Endometrial Carcinomas

(2011) Carla Bartosch et al.   ADVANCES IN ANATOMIC PATHOLOGY

Identification of Individuals at Risk for Lynch Syndrome Using Targeted Evaluations and Genetic Testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline

(2011) Scott M. Weissman et al.   Journal of Genetic Counseling

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis

(2011) Anna Yemelyanova et al.   MODERN PATHOLOGY

Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible

(2010) Martin Köbel et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes

(2010) Abdulmohsen Alkushi et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial

(2010) RA Nout et al.   LANCET

Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis

(2010) Yukiharu Todo et al.   LANCET

Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma

(2010) Geoffrey Hall et al.   PATHOLOGY

Are Uterine Risk Factors More Important Than Nodal Status in Predicting Survival in Endometrial Cancer?

(2009) Janice S. Kwon et al.   OBSTETRICS AND GYNECOLOGY

Prospective assessment of lymphatic dissemination in endometrial cancer: A paradigm shift in surgical staging

(2008) Andrea Mariani et al.   GYNECOLOGIC ONCOLOGY

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma

(2008) C. Blake Gilks et al.   HUMAN PATHOLOGY

Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1

(2008) Marjolijn J L Ligtenberg et al.   NATURE GENETICS

Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study

(2007) Nobuyuki Susumu et al.   GYNECOLOGIC ONCOLOGY